<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173158</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-030</org_study_id>
    <nct_id>NCT02173158</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy</brief_title>
  <official_title>A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous
      Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, single-arm, open-label, multicenter clinical trial to evaluate both the
      efficacy and long-term safety of lomitapide in Japanese patients with HoFH receiving
      maximally-tolerated, stable lipid-lowering therapy. This study is comprised of two phases: a
      primary 26-week Efficacy Phase followed by a 30-week Safety Phase.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in LDL-C</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Mean percent change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term safety</measure>
    <time_frame>56 Weeks</time_frame>
    <description>Assessed through findings noted on physical examination and ECG, changes in laboratory parameters and weight, change in hepatic fat as assessed by MRI, and reported AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Familial Hypercholesterolemia - Homozygous</condition>
  <arm_group>
    <arm_group_label>lomitapide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <arm_group_label>lomitapide</arm_group_label>
    <other_name>Juxtapid, Lojuxta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese male and female HoFH patients aged ≥ 18 years of age

          2. Diagnosis of functional HoFH

          3. Body weight ≥ 40 kg and &lt; 136 kg

          4. Negative pregnancy test at screening

        Exclusion Criteria:

          1. Uncontrolled hypertension

          2. History of chronic renal insufficiency

          3. History of biopsy proven cirrhosis or abnormal liver function tests (LFTs) at
             screening

          4. Any major surgical procedure occurring &lt; 3 months prior to the screening visit

          5. Cardiac insufficiency

          6. Previous organ transplantation

          7. History of a non-skin malignancy within the previous 3 years

          8. Patients who are not able to limit their alcohol intake

          9. Participation in an investigational drug study within 6 weeks prior to the screening
             visit

         10. Known significant gastrointestinal bowel disease

         11. Nursing mothers

         12. Serious or unstable medical or psychological conditions

         13. Requirement for certain prohibited medications known to be potentially hepatotoxic

         14. Use of strong or moderate inhibitors of CYP3A4

         15. Use of simvastatin at doses &gt;10 mg per day

         16. Documented diagnosis of any liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariko Harada-Shiba, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cerebral and Cardiovascular Center Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iida-shi</city>
        <state>Nagano</state>
        <zip>395-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakashi</city>
        <state>Osaka</state>
        <zip>530-00001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1142</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 17, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
